Shares of the German drug maker InflaRx (IFRX) fell sharply Wednesday after its lead drug failed to benefit patients with a debilitating skin disease in a clinical trial.

In the Phase 2 clinical trial, InflaRx tested four escalating doses of its injectable antibody drug called IFX-1 against a placebo in 179 patients with hidradenitis suppurativa, a painful skin disease characterized by inflamed hair follicles, mostly found in the armpits and groin. Involvement of the sweat glands within the follicles causes painful, pus-filled boils, nodules, and abscesses.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Adam,
    What’s the connection between Inflazrx and Moderna? Was it a spinoff, common ownership,? It doesn’t sound to me like the technology is particularly close?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy